Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study

• Status: Terminated
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

Chronic bladder pain syndrome is a chronic disabling disorder characterized by chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as persistent urgency or frequency in the absence of an identifiable cause. Chronic bladder pain syndrome severely decreases an individual's quality of life and represents a significant financial burden to those affected by it. Currently, multifactorial pathogenesis is assumed including endocrine-involvement, pelvic floor muscle irregularities, immunologic aspects and chemical causes. Corresponding to the wide spectrum of presumptive triggers, a large number of therapeutic approaches are propagated, however most are associated with limited effectiveness. Thus, treatment of BPS is a challenge and the ideal therapy remains to be elucidated. Microorganisms such as Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma genitalium remains a challenge so that these organisms may well be involved in the pathogenesis of chronic bladder pain syndrome. The investigators hypothesise that doxycycline orally for 4 weeks, including therapy of the sexual partner, can significantly relieve symptoms in women with chronic bladder pain syndrome

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Treatments: Carboxymethylcellulose Sodium; Doxycycline

Criteria

Inclusion Criteria:

• Bladder pain / suprapubic pressure or discomfort for >6months

• Urgency/urgency incontinence and/or frequency for >6months

• Written informed consent (including confirmation that the partner will also be treated and that during the treatment period sexual intercourse is only allowed using condoms)

Exclusion Criteria

• age < 18 years

• Tetracycline allergy

• Intake of a tetracycline in the last 3 months

• pregnancy

• breast feeding

• bacterial cystitis in the last 4 weeks

• urethral/vaginal/cervical/uterine and/or rectal cancer

• chemical cystitis

• tuberculous cystitis

• benign or malignant bladder tumors

• Lack of radiologic exclusion of pelvic pathology